Revised SPC: Paroven (oxerutins) 250 mg Capsules

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
29 July 2019

Abstract

The SPC has been updated to advise safety and efficacy of oxerutins (Paroven) in children and adolescents aged less than 18 years has not yet been established, and therefore lower age limit has been changed from 12 years to 18 years.